Sonoma Pharmaceuticals (SNOA) Competitors $4.47 -0.08 (-1.76%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.47 0.00 (0.00%) As of 09/12/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. ITRM, KZR, CASI, ASBP, PMN, DARE, TENX, BCAB, MIRA, and CLSDShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Aspire Biopharma (ASBP), Promis Neurosciences (PMN), Dare Bioscience (DARE), Tenax Therapeutics (TENX), BioAtla (BCAB), MIRA Pharmaceuticals (MIRA), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors Iterum Therapeutics Kezar Life Sciences CASI Pharmaceuticals Aspire Biopharma Promis Neurosciences Dare Bioscience Tenax Therapeutics BioAtla MIRA Pharmaceuticals Clearside Biomedical Sonoma Pharmaceuticals (NASDAQ:SNOA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment. Which has preferable earnings & valuation, SNOA or ITRM? Sonoma Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonoma Pharmaceuticals$14.29M0.51-$3.46M-$2.46-1.82Iterum TherapeuticsN/AN/A-$24.77M-$0.85-0.80 Do analysts recommend SNOA or ITRM? Iterum Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 1,218.68%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of SNOA or ITRM? 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 24.6% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor SNOA or ITRM? In the previous week, Iterum Therapeutics had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 2 mentions for Iterum Therapeutics and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 1.91 beat Iterum Therapeutics' score of 1.45 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Sonoma Pharmaceuticals Very Positive Iterum Therapeutics Positive Is SNOA or ITRM more profitable? Iterum Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -23.87%. Iterum Therapeutics' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sonoma Pharmaceuticals-23.87% -50.00% -16.79% Iterum Therapeutics N/A N/A -65.01% Which has more risk and volatility, SNOA or ITRM? Sonoma Pharmaceuticals has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 3.04, suggesting that its share price is 204% more volatile than the S&P 500. SummaryIterum Therapeutics beats Sonoma Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.48M$2.59B$5.86B$10.14BDividend YieldN/A56.51%5.68%4.59%P/E Ratio-1.8223.5374.5225.93Price / Sales0.51699.46547.62126.81Price / CashN/A171.1637.5660.44Price / Book1.645.3712.166.29Net Income-$3.46M$32.95M$3.28B$270.77M7 Day Performance-5.50%1.28%0.87%3.88%1 Month Performance46.08%6.09%4.96%4.88%1 Year Performance27.71%-2.15%60.75%26.01% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals0.7938 of 5 stars$4.47-1.8%N/A+41.0%$7.48M$14.29M-1.82180Positive NewsITRMIterum Therapeutics2.8366 of 5 stars$0.65-4.0%$9.00+1,284.6%-38.5%$28.98MN/A-0.7610Positive NewsShort Interest ↓KZRKezar Life Sciences3.8411 of 5 stars$3.88-1.9%$9.00+132.3%-30.3%$28.37M$7M-0.4060CASICASI Pharmaceuticals3.7624 of 5 stars$2.28-1.1%$4.00+75.1%-68.4%$28.09M$28.54M-0.79180Gap DownASBPAspire BiopharmaN/A$0.56-2.5%N/AN/A$27.77MN/A0.00N/APositive NewsPMNPromis Neurosciences3.6746 of 5 stars$0.53-2.0%$4.33+719.2%-64.8%$27.41MN/A-2.525Positive NewsShort Interest ↓DAREDare Bioscience2.2864 of 5 stars$2.03+0.2%$12.00+492.6%-37.0%$27.30M$10K-0.9530Positive NewsShort Interest ↓TENXTenax Therapeutics2.2641 of 5 stars$5.98-0.3%$17.00+184.5%+65.6%$27.25MN/A-6.499BCABBioAtla2.4599 of 5 stars$0.45-0.5%$5.00+1,003.8%-55.2%$26.60M$11M-0.4160Gap UpMIRAMIRA Pharmaceuticals3.0488 of 5 stars$1.38+0.7%$17.00+1,131.9%+8.2%$26.41MN/A-2.832News CoveragePositive NewsShort Interest ↓Gap UpCLSDClearside Biomedical2.2116 of 5 stars$0.33-9.4%$4.20+1,161.3%-76.3%$26.14M$1.66M-0.9030Stock SplitGap Down Related Companies and Tools Related Companies Iterum Therapeutics Competitors Kezar Life Sciences Competitors CASI Pharmaceuticals Competitors Aspire Biopharma Competitors Promis Neurosciences Competitors Dare Bioscience Competitors Tenax Therapeutics Competitors BioAtla Competitors MIRA Pharmaceuticals Competitors Clearside Biomedical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNOA Stock Alerts